Axsome Therapeutics (AXSM) shares are rising as there has been positive news from the FDA regarding its treatment for depression. George Tsilis joins Alex Coffey and Jenny Horne to discuss AXSM. They talk about how this is a pre-revenue company that has four drugs in the pipeline for ailments such as migraines, depression and agitation associated with Alzheimer's. They also go over how AZSM’s depression drug is a different kind of drug than the traditional drugs for depression. Tune in to find out more.
Next Gen Investing
27 Jun 2022
SHARE
The Watch List
17 May 2023
Trading 360
12 Jun 2023
The Watch List
26 Jun 2023
Market On Close
03 May 2023
Market On Close
23 May 2023
Morning Trade Live
14 Jun 2023